Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.
Publication Title
Diabetes, obesity & metabolism
Document Type
Article
Publication Date
7-1-2026
Keywords
Humans; Renal Insufficiency, Chronic; Female; Male; Benzhydryl Compounds; Middle Aged; Diabetes Mellitus, Type 2; Glucosides; Glomerular Filtration Rate; Albuminuria; Aged; Drug Therapy, Combination; Diabetic Nephropathies; Obesity; Blood Pressure; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Double-Blind Method; Adult; Cytochrome P-450 CYP11B2; Hypoglycemic Agents; blood pressure; body mass index (BMI); chronic kidney disease; glycated haemoglobin; urinary albumin.; washington; spokane
Abstract
AIMS: In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D).
MATERIALS AND METHODS: Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to < 90 mL/min/1.73 m
RESULTS: Consistent with overall study results, the largest UACR reductions were observed in 10 and 20 mg dose groups across both subgroup analyses (adjusted mean reduction 30%-51% vs. 37%-46% in the overall study). UACR reductions were consistent in participants with and without T2D (P
CONCLUSIONS: Effects of vicadrostat with or without empagliflozin on UACR, eGFR, and SBP were consistent irrespective of T2D and obesity status.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05182840.
Area of Special Interest
Kidney & Diabetes
Area of Special Interest
Digestive Health
Specialty/Research Institute
Nephrology
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Gastroenterology
DOI
10.1111/dom.70836
